These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin. Luce JM Crit Care Med; 1993 Aug; 21(8):1233-41. PubMed ID: 8339592 [TBL] [Abstract][Full Text] [Related]
27. Outcome for Gram-negative bacteraemia when following restrictive empirical antibiotic guidelines. Enoch DA; Phillimore N; Mlangeni DA; Salihu HM; Sismey A; Aliyu SH; Karas JA QJM; 2011 May; 104(5):411-9. PubMed ID: 21115461 [TBL] [Abstract][Full Text] [Related]
28. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock. Calandra T; Baumgartner JD; Glauser MP Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424 [TBL] [Abstract][Full Text] [Related]
30. A controlled trial of HA-1A in a canine model of gram-negative septic shock. Quezado ZM; Natanson C; Alling DW; Banks SM; Koev CA; Elin RJ; Hosseini JM; Bacher JD; Danner RL; Hoffman WD JAMA; 1993 May; 269(17):2221-7. PubMed ID: 8474201 [TBL] [Abstract][Full Text] [Related]
31. Measuring the effect of inappropriate initial antibiotic therapy on outcomes of patients with Gram-negative sepsis: An imprecise science. Sexton DJ; Miller BA; Anderson DJ Crit Care Med; 2011 Jan; 39(1):199-200. PubMed ID: 21178535 [No Abstract] [Full Text] [Related]
33. Comparison of the efficacy, safety, and therapeutic usage of HA-1A and E5 in the treatment of gram-negative sepsis. Quintiliani R; Cooper B; Maderazo E; Nightingale C Hosp Formul; 1992 Jan; 27(1):49-52, 54, 57-60. PubMed ID: 10116116 [TBL] [Abstract][Full Text] [Related]
34. Search for sepsis drugs goes on despite past failures. Stone R Science; 1994 Apr; 264(5157):365-7. PubMed ID: 8153620 [No Abstract] [Full Text] [Related]
35. [A cost-effectiveness analysis of treatment with antiendotoxin monoclonal antibodies in gram-negative sepsis]. Tebas P Med Clin (Barc); 1993 Dec; 101(19):757-8. PubMed ID: 8289526 [No Abstract] [Full Text] [Related]
36. [Monoclonal antibodies in the treatment of septic shock]. Trilla A; Alonso P Med Clin (Barc); 1992 Dec; 99(20):778-80. PubMed ID: 1460950 [No Abstract] [Full Text] [Related]
37. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody. Gorelick KJ; Chmel H Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775 [TBL] [Abstract][Full Text] [Related]
38. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. Gudiol C; Tubau F; Calatayud L; Garcia-Vidal C; Cisnal M; Sánchez-Ortega I; Duarte R; Calvo M; Carratalà J J Antimicrob Chemother; 2011 Mar; 66(3):657-63. PubMed ID: 21193475 [TBL] [Abstract][Full Text] [Related]
39. Evaluating the cost containment potential of clinical guidelines. Carpenter CE; Nash DB; Johnson NE QRB Qual Rev Bull; 1993 Apr; 19(4):119-23. PubMed ID: 8493026 [TBL] [Abstract][Full Text] [Related]